Verbena Attenuates Adriamycin-Induced Renal Tubular Injury via Inhibition of ROS-ERK1/2-NLRP3 Signal Pathway. (28th September 2022)

• Record Type: Journal Article
• Authors: Zhou, Yicen; Wu, Qijing; Du, Zhenfang; Huang, Min; Gao, Kun; Ma, Xiaowei; Zhang, Hui; Qiang, Sheng; Sun, Wei
• Other Names: Yuan Yanggang Academic Editor.
• Is Part Of: Evidence-based complementary and alternative medicine. Volume 2022(2022)
• Publication Date: 2022-09-28
• Subjects: Alternative medicine -- Periodicals; 615.505
• DOI: 10.1155/2022/7760945
• Languages: English
• ISSNs: 1741-427X

Abstract

Abstract : Chronic kidney disease (CKD) has become a global public health problem. Tubular epithelial cell injury plays a vital role in the progression and prognosis of CKD. Therapies to protect tubular cells is the key to delaying CKD progression. Our study found that verbena, a natural traditional Chinese herb, has a potential reno-protective role in kidney diseases. However, the detailed mechanism remains unknown. In the current study, we employed adriamycin (ADR)-induced renal tubular cell injury to mimic the conditions of tubular injury in vitro. Results showed that total aqueous exact of verbena (TAEV) ameliorated ADR-induced cell disruption, loss of cellular viability, and apoptosis via inhibition of ROS-ERK1/2-mediated activation of NLRP3 signal pathway, suggesting that TAEV serves as a promising renoprotective agent in delaying the progression of CKD, while ROS-ERK1/2-mediated NLRP3 signal pathway might be a novel target in treating kidney diseases.